首页 > 市场调查报告书 > 製药

感染疾病呼吸器

市场调查报告书

商品编码

1729663

人类偏肺病毒 (hMPV) 治疗市场按治疗类型、给药途径、最终用户、分销管道和地区划分

Human Metapneumovirus (hMPV) Therapeutics Market, By Treatment Type, By Route of Administration, By End User, By Distribution Channel, By Geography

出版日期: 2025年04月29日 | 出版商:

Coherent Market Insights | 英文 145 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2025 年全球人类偏肺病毒 (hMPV) 治疗市场规模估计为 4.941 亿美元，预计到 2032 年将达到 7.677 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 6.5%。

报告范围		报告详细信息
基准年	2024	2025年的市场规模	4.941亿美元
效能数据	从2020年到2024年	预测期	2025年至2032年
预测期：2025-2032年复合年增长率：	6.50%	2032年价值预测	7.677亿美元

数字。 2025年人类偏肺病毒（hMPV）治疗药物市场占有率（%）

人类亚肺病毒 (hMPV) 是一种高度传染性的呼吸道病毒病原体，在感染疾病引起上呼吸道和下感染疾病。 hMP 病毒于 2001 年在荷兰一名幼儿的呼吸道感染疾病中首次被发现。自此，hMPV 被世界公认为儿童和免疫力缺乏患者急性呼吸道感染疾病的重要病毒病原体。由于 hMPV 与其他呼吸道病毒（如呼吸道融合细胞病毒(RSV)）有相似之处，因此 hMPV感染疾病经常被漏诊或误诊。然而，分子诊断技术的最新进展提高了我们对 hMPV 流行病学和疾病负担的认识。由于目前尚无核准的疫苗或治疗方法，随着替代治疗方法活性化力度的加大，人类亚肺病毒 (hMPv) 治疗市场预计将在未来几年内大幅成长。

市场动态：

全球人类偏肺病毒 (hMPV) 治疗市场受到疾病盛行率上升、缺乏核准的治疗方案、正在进行的候选药物研发活动以及疫苗开发公共和私人资金增加的推动。然而，开发新药的成本高、疫苗开发的成功率难以预测以及临床试验的潜在挑战可能会抑制市场成长。该市场还为公司提供了机会，透过持续的发现研究来识别新药，透过孤儿药指定专注于儿科适应症，并与学术机构合作进行药物开发。向呼吸系统疾病负担日益加重的新兴市场进行地理扩张将进一步补充长期的商业机会。此外，诊断方法的创新、感染动力学的研究以及联合治疗的开发都有可能扩大市场。

本研究的主要特点

本报告对全球人类偏肺病毒 (hMPV) 治疗市场进行了详细分析，并提供了预测期 (2025-2032) 的市场规模和年复合成长率（CAGR%），以 2024 年为基准年。
它揭示了各个领域的潜在商机，并解释了该市场有吸引力的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的重要见解。
全球人类偏肺病毒 (hMPV) 治疗市场中的主要企业是根据公司亮点、产品系列、关键亮点、绩效和策略等参数进行分析的。
本报告的见解将使负责人和企业经营团队能够就未来的产品发布、高端市场策略、市场扩张和行销策略做出明智的决策。
全球人类偏肺病毒 (hMPV) 治疗市场报告迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 494.1 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	6.50%	2032 Value Projection:	USD 767.7 Mn

Human metapneumovirus (hMPV) is a highly contagious respiratory viral pathogen that causes upper and lower respiratory tract infections worldwide. It was first identified in 2001 in young Dutch children with respiratory tract infections. Since then, hMPV has been recognized as an important viral agent of acute respiratory tract infection in pediatric patients and immuno-compromised individuals globally. Due to its close similarity to other respiratory viruses like respiratory syncytial virus (RSV), hMPV infections often remain undiagnosed or misdiagnosed. However, recent advances in molecular diagnostic techniques have enhanced understanding of hMPV epidemiology and disease burden. With no approved vaccines or treatments currently available, the human metapneumovirus (hmpv) therapeutics market is poised to grow significantly in the coming years as research efforts to develop therapeutic alternatives gain momentum.

Market Dynamics:

The global human metapneumovirus (hMPV) therapeutics market is driven by rising disease prevalence, lack of approved treatment options, ongoing research & development activities for drug candidates, and growing public-private funding for vaccine development. However, high development costs for new drugs, unpredictable success rate for vaccine development, and potential challenges in clinical trials can restrain market growth. The market also presents opportunities for players through ongoing discovery & research to identify novel drugs, focus on pediatric indication with orphan drug designation, and collaborations with academic institutions for drug development. Geographic expansion into emerging markets with growing respiratory disease burden will further supplement business opportunities in the long run. Innovation in diagnostics, research on transmission dynamics, and development of combination therapies also hold promise to expand the market size.

Key Features of the Study:

This report provides in-depth analysis of the global human metapneumovirus (hMPV) therapeutics market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global human metapneumovirus (hMPV) therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include GSK (GlaxoSmithKline), Merck & Co., Pfizer Inc., Novartis AG, Sanofi S.A., Johnson & Johnson, Roche Holding AG, AstraZeneca PLC, AbbVie Inc., Regeneron Pharmaceuticals, Takeda Pharmaceutical Company, Amgen Inc., Eli Lilly and Company, Bayer AG, and Biogen Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global human metapneumovirus (hMPV) therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Market Segmentation

Treatment Type Insights (Revenue, USD Mn, 2020 - 2032)
- Antiviral Drugs
- Nucleotide analogs
- Protease inhibitors
- Polymerase inhibitors
- Vaccines
- Live-attenuated vaccines
- Inactivated vaccines
- Recombinant vaccines
- Supportive Therapies
- Monoclonal antibodies
- Immunomodulators
Route of Administration Insights (Revenue, USD Mn, 2020 - 2032)
- Oral
- Intravenous
- Inhalation
End User Insights (Revenue, USD Mn, 2020 - 2032)
- Hospitals and Clinics
- Diagnostic and Reference Laboratories
- Academic and Research Institutions
- Others
Regional Insights (Revenue, USD Mn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Company Profiles:
- GSK (GlaxoSmithKline)
- Merck & Co.
- Pfizer Inc.
- Novartis AG
- Sanofi S.A.
- Johnson & Johnson
- Roche Holding AG
- AstraZeneca PLC
- AbbVie Inc.
- Regeneron Pharmaceuticals
- Takeda Pharmaceutical Company
- Amgen Inc.
- Eli Lilly and Company
- Bayer AG
- Biogen Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Human Metapneumovirus (hMPV) Therapeutics Market, By Treatment Type
- Global Human Metapneumovirus (hMPV) Therapeutics Market, By Route of Administration
- Global Human Metapneumovirus (hMPV) Therapeutics Market, By End User
- Global Human Metapneumovirus (hMPV) Therapeutics Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Driver
- Restraint
- Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Human Metapneumovirus (hMPV) Therapeutics Market, By Treatment Type, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Antiviral Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Nucleotide analogs
Protease inhibitors
Polymerase inhibitors
Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Live-attenuated vaccines
Inactivated vaccines
Recombinant vaccines
Supportive Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Monoclonal antibodies
Immunomodulators

5. Global Human Metapneumovirus (hMPV) Therapeutics Market, By Route of Administration, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Inhalation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

6. Global Human Metapneumovirus (hMPV) Therapeutics Market, By End User, 2020-2032, (USD Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Diagnostic and Reference Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Academic and Research Institutions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Human Metapneumovirus (hMPV) Therapeutics Market, By Region, 2020 - 2032, Value (USD Mn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Mn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country 2020 - 2032, Value (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country 2020 - 2032, Value (USD Mn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country 2020 - 2032, Value (USD Mn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country 2020 - 2032, Value (USD Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country 2020 - 2032, Value (USD Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Treatment Type, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
- Market Size and Forecast, By Country/Region 2020 - 2032, Value (USD Mn)
  - South Africa
  - North Africa
  - Central Africa

8. Competitive Landscape

GSK (GlaxoSmithKline)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co.
Pfizer Inc.
Novartis AG
Sanofi S.A.
Johnson & Johnson
Roche Holding AG
AstraZeneca PLC
AbbVie Inc.
Regeneron Pharmaceuticals
Takeda Pharmaceutical Company
Amgen Inc.
Eli Lilly and Company
Bayer AG
Biogen Inc.

9. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

10. References and Research Methodology

References
Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/价格

人类偏肺病毒 (hMPV) 治疗市场按治疗类型、给药途径、最终用户、分销管道和地区划分